Suven Life Sciences has been granted three product patents, which includes two from Eurasia and one from Canada. These patents correspond to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and are valid till 2027.

The granted claims of the patents include the class of selective 5-HT compounds, discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like alzheimer's disease, attention deficient hyperactivity disorder (ADHD), huntington's disease, parkinson disease and schizophrenia.

With these new patents, Suven has a total of 10 granted product patents from Canada and 12 granted product patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase I or phase II.

Mr Venkat Jasti, CEO, Suven Life Sciences said that, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and with huge market potential globally."

Suven currently have 12 internally-discovered therapeutic drug candidates in the pre-clinical stage of development for targeting conditions such as ADHD, dementia, depression, huntington's disease, parkinson's disease and obesity in addition to developmental candidate SUVN-502 for alzheimer's disease and schizophrenia.